GC CELL CORPORATION
Cell and gene therapy specialist with integrated CDMO, bio-logistics, and cell banking.
144510 | KO
Overview
Corporate Details
- ISIN(s):
- KR7144510005
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 이현로30번길 107, 용인시
- Website:
- http://gccell.com/en/main.do
- Sector:
- Manufacturing
Description
GC CELL CORPORATION specializes in cell and gene therapy, providing a fully integrated value chain from research to commercialization. The company's core offerings include end-to-end Contract Development and Manufacturing Organization (CDMO) services for autologous and allogeneic cell therapies, comprehensive bio-logistics, and cell banking. Its integrated model supports partners throughout the entire drug life cycle, from initial development and manufacturing to clinical trials and commercial distribution. In addition to its service-based solutions, GC CELL develops proprietary cell therapy products, including Immuncell-LC, an adjuvant therapy for hepatocellular carcinoma. The company focuses on advancing treatments in areas such as immune-oncology and delivering customized solutions to enhance patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-11-14 00:00 |
분기보고서 (2023.09)
|
Korean | 1.1 MB | ||
| 2023-11-01 00:00 |
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.5 KB | ||
| 2023-10-17 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청)(AB-201의 국내 제 1상 임상시험계획승인신청(IND))
|
Korean | 10.3 KB | ||
| 2023-10-17 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청)(AB-201의 호주 제 1상 임상시험계획승인신청(IND))
|
Korean | 10.8 KB | ||
| 2023-10-16 00:00 |
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2023-08-14 00:00 |
반기보고서 (2023.06)
|
Korean | 1.2 MB | ||
| 2023-08-04 00:00 |
기업설명회(IR)개최
|
Korean | 6.8 KB | ||
| 2023-08-01 00:00 |
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.5 KB | ||
| 2023-07-20 00:00 |
투자판단관련주요경영사항(임상시험계획자진취하등)(CT303(동종편도유래중간엽줄기세포_판상형 건선 환자대상)의 제1상 임상시험 조기종료)
|
Korean | 11.8 KB | ||
| 2023-07-05 00:00 |
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2023-06-27 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.3 KB | ||
| 2023-06-01 00:00 |
수시공시의무관련사항(공정공시)(주주가치 제고를 위한 주주환원 정책 안내)
|
Korean | 5.3 KB | ||
| 2023-05-12 00:00 |
투자판단관련주요경영사항(임상시험계획자진취하등)(CT303(동종편도유래중간엽줄기세포)의 제1상 임상시험 조기종료)
|
Korean | 11.6 KB | ||
| 2023-05-12 00:00 |
분기보고서 (2023.03)
|
Korean | 913.4 KB | ||
| 2023-04-28 00:00 |
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 16.3 KB |
Automate Your Workflow. Get a real-time feed of all GC CELL CORPORATION filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GC CELL CORPORATION
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GC CELL CORPORATION via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
